Omeros
Market cap $1.04B 74.5M shares (10-Q, Nov 11, 2026) × $13.92 close Nov 17, 2026
Most recent annual filing: 2026-01-15
- OncotoX-AML trial startlate 2027OncotoX-AML trial start, late 2027, routine
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (6 active programs)
Technology platforms
T-CAT
Targeted complement activating therapy — a new class of recombinant antibodies designed to harness complement activation to kill pathogens directly, including bacteria, fungi, viruses, and parasites; focus on drug-resistant organisms and multidrug-resistant organisms; infectious disease treatment
OncotoX-AML
Novel oncology platform targeting acute myeloid leukemia; lead candidate OMS805 demonstrated superior efficacy to AML standards of care across tumor-bearing animal models and in vitro human AML cell-line studies, independent of AML-related genetic mutations
OncotoX
Oncology platform focused on developing novel proprietary large molecule therapeutics designed to selectively target and kill dividing cancer cells; lead indication acute myeloid leukemia; independent of myeloid cell genetic mutations
Discontinued (1)
- zaltenibart — undisclosed · divested to Novo Nordisk Healthcare AG via Asset Purchase and Licensing Agreement completed November 25, 2025
Capital (as filed)
- Cash
- $5.1M cash and cash equivalents · Sep 30, 2026 (10-Q)
- Short-term investments
- $90.2M Sep 30, 2026
- Operating cash flow
- $13.3M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
- As stated in coverage
- $95.3M cash per the update of Nov 16, 2026 — the company's own words as read there, not the filed figure
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Biotech Distilled coverage (12)
- 2026-11-17 UPDATE: Omeros (OMER) - The Slope Bends, the Cash Engine Turns On 🔒 Paid
- 2026-10-16 UPDATE: Omeros (OMER) - Europe’s Door Closes ★ Distilled Pro
- 2026-08-13 UPDATE: Omeros (OMER) — The Slope Question Gets Answered 🔒 Paid
- 2026-08-03 UPDATE: Omeros (OMER) — NTAP Lands, and It’s Bigger Than I Modeled 🔒 Paid
- 2026-07-06 UPDATE: Omeros (OMER) — Round Two on the Convert, and a Hint About Non-Dilutive Debt 🔒 Paid
- 2026-06-26 UPDATE: Omeros (OMER) — CHMP Says No, Re-Examination Coming 🔒 Paid
- 2026-06-18 UPDATE: Omeros (OMER) — Buying Back the Convert at 2x Face 🔒 Paid
- 2026-05-14 UPDATE: Omeros (OMER) - First Launch Quarter Prints $9.9M, NTAP Tailwind Stacks on the J-Code 🔒 Paid
- 2026-04-18 UPDATE: Omeros (OMER) – Permanent J-Code Clears the Runway 🔒 Paid
- 2026-04-05 UPDATE: Omeros (OMER) – Q4/YE 2025 Earnings, Launch Strategy, and Pipeline Nuance 🔒 Paid
- 2026-02-21 UPDATE: Omeros (OMER) - OncotoX Platform Shows Proof of Concept 🔒 Paid
- 2025-12-26 Omeros Corporation (OMER): Scientific Due Diligence for Lead and Pipeline Products 🔒 Paid
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Verdict history (12 calls)
Every verdict Biotech Distilled has published on Omeros, oldest first — the full history, never a selection. How calls are scored: the track record.
- 2025-12-26 Buy core Omeros Corporation (OMER): Scientific Due Diligence for Lead and Pipeline Products FDA approval transforms Omeros from a binary regulatory gamble into a commercial-stage monopoly with the only approved therapy for TA-TMA, a clean balance sheet, and a 15-year patent runway.
- 2026-02-21 Buy core UPDATE: Omeros (OMER) - OncotoX Platform Shows Proof of Concept OncotoX primate data validates a new pipeline vertical but does not change the primary thesis; YARTEMLEA commercial execution remains the driver.
- 2026-04-05 Buy core UPDATE: Omeros (OMER) – Q4/YE 2025 Earnings, Launch Strategy, and Pipeline Nuance Financial de-risking is complete with $171.8M cash and debt cleaned up; hyper-targeted commercial rollout of YARTEMLEA into top-80 transplant centers is tracking the monopoly thesis.
- 2026-04-18 Buy core UPDATE: Omeros (OMER) – Permanent J-Code Clears the Runway Permanent J-code J1289 effective July 1 directly removes the billing friction that was the core bear case, accelerating the H2 2026 commercial ramp.
- 2026-05-14 Buy core UPDATE: Omeros (OMER) - First Launch Quarter Prints $9.9M, NTAP Tailwind Stacks on the J-Code $9.9M net sales in the launch quarter with 30 ordering accounts, no REMS or boxed warning on the actual label, and NTAP stacking on the J-code make the thesis tracking ahead of the December model.
- 2026-06-18 Buy core UPDATE: Omeros (OMER) — Buying Back the Convert at 2x Face Commercial thesis unchanged with YARTEMLEA launching and reimbursement infrastructure building, but management spending ~$34M to retire $16M of deeply in-the-money convert narrows the cash cushion heading into the most important launch quarters.
- 2026-06-26 Buy core UPDATE: Omeros (OMER) — CHMP Says No, Re-Examination Coming CHMP negative opinion removes Europe as a re-rate catalyst but does not affect the U.S. monopoly base case, which was always the foundation of the thesis.
- 2026-07-06 Buy core UPDATE: Omeros (OMER) — Round Two on the Convert, and a Hint About Non-Dilutive Debt Tranche 1 of the convert repurchase closed cheaper than expected and tranche 2 is signed; management's intent to replace convert cash with non-convertible debt could preserve the launch cushion while permanently removing dilution overhang.
- 2026-08-03 Buy core UPDATE: Omeros (OMER) — NTAP Lands, and It's Bigger Than I Modeled NTAP final rule confirms up to $287,079 per eligible Medicare inpatient effective October 1, completing the reimbursement stack and dismantling the original billing-friction bear case ahead of the imminent Q2 print.
- 2026-08-13 Buy core UPDATE: Omeros (OMER) — The Slope Question Gets Answered Q2 net sales of $28.5M (+190% sequential) with 73 ordering accounts achieved before any reimbursement tailwinds, confirming the launch slope and dismantling the original bear case entirely.
- 2026-10-16 Buy core UPDATE: Omeros (OMER) - Europe's Door Closes CHMP re-examination failed, writing Europe off entirely, but the U.S. monopoly thesis is intact with $28.5M Q2 net sales, 73 ordering accounts, adjusted profitability, and NTAP now live; supply capacity is the new risk to watch.
- 2026-11-17 Buy core UPDATE: Omeros (OMER) - The Slope Bends, the Cash Engine Turns On Q3 net sales of $35.9M (+26% sequential) with 109 ordering accounts and $13.3M operating cash flow confirm the launch is self-funding and broadening, with growth slowing as expected after the prevalent-patient backlog clears.
- Long call · opened Dec 26, 2025 at $15.71 · -11.4% vs XBI +16.2% (Nov 17, 2026)
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Filings & releases (25)
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from May 11, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →
- Nov 16, 2026ReleaseOmeros Corporation Reports Third Quarter 2026 Financial Results→ BD updateSummary on the 8-K
- Nov 16, 20268-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1→ BD updateYARTEMLEA posted $35.9M net / $41.8M gross in Q3 — a third consecutive quarter of growth, 109 ordering accounts, and $4.5M operating income — with the CEO confirming Q4 momentum is continuing and a new 2027 outpatient reimbursement tailwind on the horizon.
- Nov 16, 202610-QQuarterly report→ BD updateSummary on the 8-K
- Nov 10, 2026ReleaseOmeros Corporation to Announce Third Quarter Financial Results on November 16, 2026
- Oct 30, 20268-KCurrent report: officer / director change
- Oct 16, 2026ReleaseOmeros Corporation Receives CHMP Negative Opinion Following Re-Examination of European Marketing Authorization Application for Narsoplimab in TA-TMA→ BD updateThe CHMP has issued a second negative opinion on narsoplimab's European MAA following re-examination — definitively closing the European approval pathway under the current data package, with a procedurally controversial process that withheld Omeros's own patient-level data from the expert panel it convened.BD extracted 1 program update from this document → OMER pipeline
- Aug 13, 20268-KCurrent report: officer / director change
- Aug 12, 2026ReleaseOmeros Corporation Reports Second Quarter 2026 Financial Results
- Aug 12, 20268-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1
- Aug 12, 202610-QQuarterly reportBD extracted 1 program update from this document → OMER pipeline
- Aug 10, 2026ReleaseOmeros Corporation to Announce Second Quarter Financial Results on August 12, 2026
- Aug 3, 2026ReleaseCMS Grants New Technology Add-On Payment (NTAP) Status to YARTEMLEA®
- Jul 20, 20268-KCurrent report: other events
- Jul 6, 20268-KCurrent report: other events
- Jun 26, 2026ReleaseOmeros Corporation Announces Update on European Marketing Authorization Application for Narsoplimab in TA-TMABD extracted 1 program update from this document → OMER pipeline
- Jun 25, 20268-KCurrent report: shareholder vote
- Jun 18, 20268-KCurrent report: other events
- Jun 15, 2026ReleaseOmeros Announces Webcast Details for Annual Meeting of Shareholders
- May 13, 2026ReleaseOmeros Corporation Reports First Quarter 2026 Financial Results
- May 13, 20268-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1
- May 13, 202610-QQuarterly report
- May 11, 2026ReleaseOmeros Corporation to Announce First Quarter Financial Results on May 13, 2026
- Apr 30, 2026DEF 14AProxy statement
- Mar 31, 20268-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1
- Mar 31, 202610-KAnnual report
5 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)
- Aug 13, 2026S-8Employee plan registration
- Jul 29, 2026SCHEDULE 13G/A13G amendment
- Apr 30, 2026ARSAnnual report to shareholders
- Apr 23, 2026SCHEDULE 13G/A13G amendment
- Mar 27, 2026SCHEDULE 13G/A13G amendment